Health Care Knowledge

  Enhertu (Fam-trastuzumab deruxtecan-nxki) has been developed by joining a couple of different types of anti-cancer medicines together to develop one medicine named antibody-drug conjugate (ADC). Enhertu is chemotherapy and is also a targeted therapy anti-cancer medicine. The medicine is commercially available as an injection: 100 mg lyophilized powder in a single-dose vial. Enhertu injection cost in India is calculated on behalf of the specific patient's needs. Enhertu is an FDA-approved medicinal product that is widely prescribed for multiple cancer treatments. Multiple indications of Enhertu are as follows: HER2-positive Breast Cancer:  Enhertu is used for the treatment of breast cancer in adults that cannot be eliminated by surgery or that has progressed to other parts of the body (metastatic) and patients have already been treated with an anti-HER2 breast cancer therapy: for their metastatic disease, or have breast cancer that has returned during or within six months of comp

  Overview of Enhertu: Enhertu contains the active ingredient Trastuzumab deruxtecan. It is FDA-approved pharmaceutical drug that is recommended for several types of cancer. This medication is used in the management of HER2+ Metastatic Breast Cancer, HER2-Low Metastatic Breast Cancer, HER2+ Advanced Stomach Cancer, and HER2-Mutant Metastatic Lung Cancer. The medicine Enhertu is commercially supplied as 100 mg vials in the market and administered through IV infusions.  Enhertu 100 mg   is an advanced medicine that can be available on valid prescriptions only. It is developed by the company Daiichi Sankyo and widely promoted by AZ (AstraZeneca) across the globe. This  HER2-directed antibody and topoisomerase inhibitor conjugate work uniquely, by inhibiting HER2/ neu signaling and eventually killing unhealthy cells. It is not determined if this medicinal product is safe and promising in children. The  price of Enhertu in India   is specified on behalf of international trends and prices. S

  Note:  It is not advisable to substitute Trodelvy injection for or use with other medicinal products that are known for containing irinotecan or its active metabolite SN-38. Proposed Dosage of Trodelvy: The proposed dosage of Trodelvy is 10 mg/kg. The dosage needs to be administered as an intravenous infusion once a week on the 1st & 8th Days of 21-day treatment cycles. Continue treatment with trodelvy 180 mg until the disease progresses or has unacceptable adverse reactions. Avoid administering Trodelvy at doses of more than 10 mg/kg. The medicine Trodelvy is for intravenous use only. This medicinal product is not for use as an intravenous push or bolus.  Initial Infusion:  Administer trodelvy infusion over three hours. Assess respective patients throughout the infusion and a minimum of 30 minutes following the initial dose for signs-symptoms of infusion-related reactions.  Subsequent Infusions:  Administer trodelvy infusion over 60-120 minutes in case previous infusions were t